Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the GLP-1 and non-GLP-1 effects of LAF237 on glucagon
secretion, using treatment observations of the overall glycemic response.